141 related articles for article (PubMed ID: 26787390)
1. Prostate cancer: Changing standard of care in hormone-sensitive disease.
Thoma C
Nat Rev Urol; 2016 Feb; 13(2):61. PubMed ID: 26787390
[No Abstract] [Full Text] [Related]
2. Defining new standards of care for men with prostate cancer.
Scher HI
Lancet; 2016 Mar; 387(10024):1135-7. PubMed ID: 27025318
[No Abstract] [Full Text] [Related]
3. STAMPEDE trial and patients with non-metastatic prostate cancer.
Gandaglia G; Fossati N; Suardi N; Montorsi F; Briganti A
Lancet; 2016 Jul; 388(10041):234-5. PubMed ID: 27479564
[No Abstract] [Full Text] [Related]
4. STAMPEDE trial and patients with non-metastatic prostate cancer - Authors' reply.
James ND; Sydes MR; Clarke NW; Mason MD; Parmar MK
Lancet; 2016 Jul; 388(10041):235-6. PubMed ID: 27479566
[No Abstract] [Full Text] [Related]
5. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James ND; Sydes MR; Clarke NW; Mason MD; Dearnaley DP; Spears MR; Ritchie AW; Parker CC; Russell JM; Attard G; de Bono J; Cross W; Jones RJ; Thalmann G; Amos C; Matheson D; Millman R; Alzouebi M; Beesley S; Birtle AJ; Brock S; Cathomas R; Chakraborti P; Chowdhury S; Cook A; Elliott T; Gale J; Gibbs S; Graham JD; Hetherington J; Hughes R; Laing R; McKinna F; McLaren DB; O'Sullivan JM; Parikh O; Peedell C; Protheroe A; Robinson AJ; Srihari N; Srinivasan R; Staffurth J; Sundar S; Tolan S; Tsang D; Wagstaff J; Parmar MK;
Lancet; 2016 Mar; 387(10024):1163-77. PubMed ID: 26719232
[TBL] [Abstract][Full Text] [Related]
6. Cabazitaxel for castration-resistant prostate cancer.
Froehner M; Wirth MP
Lancet; 2011 Jan; 377(9760):121-2; author reply 122-3. PubMed ID: 21215875
[No Abstract] [Full Text] [Related]
7. Cabazitaxel for castration-resistant prostate cancer.
Shigeta K; Miura Y; Naito Y; Takano T
Lancet; 2011 Jan; 377(9760):121; author reply 122-3. PubMed ID: 21215876
[No Abstract] [Full Text] [Related]
8. [Optimal treatment for elderly high-risk prostate cancer patients].
Soga N; Sugimura Y
Gan To Kagaku Ryoho; 2007 Mar; 34(3):387-92. PubMed ID: 17353629
[TBL] [Abstract][Full Text] [Related]
9. Metastatic prostate cancer in 2015: The new and the old that is new again.
Graff JN; Beer TM
Nat Rev Clin Oncol; 2016 Feb; 13(2):73-4. PubMed ID: 26718107
[No Abstract] [Full Text] [Related]
10. Bisphosphonates in prostate cancer: where are we and where should we go?
Saad F
J Natl Cancer Inst; 2003 Sep; 95(17):1262-3. PubMed ID: 12953073
[No Abstract] [Full Text] [Related]
11. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
12. Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
Yuasa T
Int J Urol; 2009 Sep; 16(9):731-2. PubMed ID: 19769657
[No Abstract] [Full Text] [Related]
13. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
Kamba T; Kamoto T; Maruo S; Kikuchi T; Shimizu Y; Namiki S; Fujimoto K; Kawanishi H; Sato F; Narita S; Satoh T; Saito H; Sugimoto M; Teishima J; Masumori N; Egawa S; Sakai H; Okada Y; Terachi T; Ogawa O;
Int J Clin Oncol; 2017 Feb; 22(1):166-173. PubMed ID: 27614621
[TBL] [Abstract][Full Text] [Related]
14. Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms?
Ural AU; Avcu F
Acta Oncol; 2006; 45(4):491-2. PubMed ID: 16760189
[No Abstract] [Full Text] [Related]
15. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
[TBL] [Abstract][Full Text] [Related]
17. [Combined treatment of metastatic hormone-resistant prostate cancer].
Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
[No Abstract] [Full Text] [Related]
18. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
Matveev BP; Bukharkin BV
Vopr Onkol; 1998; 44(5):537-40. PubMed ID: 9884710
[TBL] [Abstract][Full Text] [Related]
19. Decrease in the haemoglobin level in haemodialysis patients undergoing antiandrogen therapy.
Teruel JL; Cano T; Marcén R; Villafruela JJ; Rivera M; Fernández-Juarez G; Ortuño J
Nephrol Dial Transplant; 1997 Jun; 12(6):1262-3. PubMed ID: 9198065
[No Abstract] [Full Text] [Related]
20. [Chemotherapy of the hormone-refractory prostate cancer].
Heine K; Wolff JM
Aktuelle Urol; 2004 Jun; 35(3):209-14. PubMed ID: 15258854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
